Market Snapshot: Migraine Prevention Therapies’ Slow Road To Blockbuster Status
Executive Summary
Aimovig, Emgality and Ajovy have been on the market for more than a year, but are still far from blockbusters even though millions of patients are eligible for treatment – and at least one new competitor is coming.
You may also be interested in...
Amgen Has Relatively Smooth Sailing In Q2 Despite COVID-19 Headwinds
Amgen reported a 6% year-over-year increase in second quarter sales despite pandemic-related declines for several drugs as newer product gains and Otezla righted a rocky ship.
Biohaven’s Nurtec May Be First Migraine Drug For Acute Treatment And Prevention
Approved in February as an on-demand remedy, Nurtec will be filed for migraine prevention after success in Phase III. It could be the first oral preventive therapy and first dual purpose migraine drug.
Biohaven’s Oral CGRP Inhibitor Nurtec ODT Approved In The US For Acute Migraine
The fast-dissolving tablet will launch in early March. Its list price is not available but based on pricing for Allergan’s oral anti-CGRP Ubrelvy, ICER has said Biohaven’s rimegepant is likely to be cost-effective.
Need a specific report? 1000+ reports available
Buy Reports